The earnings call was largely positive, with significant revenue growth for ARCALYST, successful milestone achievements, and promising pipeline developments. However, there is some competitive pressure and uncertainty regarding future patient retention strategies.

Company Guidance -

Q3 2025

During the second quarter of 2025, Kiniksa Pharmaceuticals reported a net revenue of $156.8 million, marking a $19 million increase from the first quarter and a 52% year-over-year growth. The company surpassed $1 billion in cumulative net sales for ARCALYST, the first FDA-approved therapy for recurrent pericarditis, and adjusted its full-year 2025 net sales guidance for ARCALYST to between $625 million and $640 million. The penetration into the multiple recurrence population increased to 15%, up from 13% at the end of 2024. The payer approval rate remained above 90%, with patient compliance over 85% and an average therapy duration of approximately 30 months. Kiniksa also initiated Phase II/III clinical trials for KPL-387, aiming for a potential launch in the 2028-2029 timeframe. Financially, the company reported a net income of $17.8 million, compared to a net loss of $3.9 million a year ago, with a cash balance increase to $307.8 million.

Strong ARCALYST Revenue Growth

ARCALYST achieved $156.8 million in net revenue for Q2 2025, a 52% year-over-year increase and a $19 million increase over the previous quarter. The company raised its full-year revenue guidance to between $625 million and $640 million.

Milestone Achievement

Kiniksa surpassed $1 billion in cumulative net sales for ARCALYST, marking significant commercial success since its launch.

Pipeline Progress with KPL-387

Initiated and began recruiting for a Phase II/III clinical trial of KPL-387 for recurrent pericarditis, with data expected in the second half of next year.

Increase in Prescriber Base

More than 325 additional healthcare professionals wrote their first ARCALYST prescription in Q2, bringing the total number of prescribers to over 3,475.

Financial Performance

Net income was $17.8 million in Q2 2025 compared to a net loss of $3.9 million a year ago. Cash balance increased by approximately $40 million to $307.8 million.

Kiniksa Pharmaceuticals (KNSA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KNSA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	0.33 / -	-0.18	―	―	―
Jul 29, 2025	2025 (Q2)	0.22 / 0.23	-0.06	483.33% (+0.29)
Apr 29, 2025	2025 (Q1)	0.13 / 0.11	-0.25	144.00% (+0.36)
Feb 25, 2025	2024 (Q4)	0.02 / -0.12	0.35	-134.29% (-0.47)
Oct 29, 2024	2024 (Q3)	0.02 / -0.18	-0.2	10.00% (+0.02)
Jul 23, 2024	2024 (Q2)	-0.08 / -0.06	0.21	-128.57% (-0.27)
Apr 23, 2024	2024 (Q1)	-0.08 / -0.25	-0.18	-38.89% (-0.07)
Feb 28, 2024	2023 (Q4)	-0.10 / 0.35	0.06	483.33% (+0.29)
Oct 31, 2023	2023 (Q3)	-0.17 / -0.20	3.23	-106.19% (-3.43)
Jul 25, 2023	2023 (Q2)	-0.14 / 0.21	-0.29	172.41% (+0.50)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KNSA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$27.04	$30.37	+12.32%
Apr 29, 2025	$21.47	$25.88	+20.54%
Feb 25, 2025	$19.63	$19.72	+0.46%
Oct 29, 2024	$27.59	$23.26	-15.69%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kiniksa Pharmaceuticals (KNSA) report earnings?

Kiniksa Pharmaceuticals (KNSA) is schdueled to report earning on Nov 04, 2025, Before Open (Confirmed).

What is Kiniksa Pharmaceuticals (KNSA) earnings time?

Kiniksa Pharmaceuticals (KNSA) earnings time is at Nov 04, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KNSA EPS forecast?

KNSA EPS forecast for the fiscal quarter 2025 (Q3) is 0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing